

EMA/477712/2010

European Medicines Agency decision

P/167/2010

of 3 September 2010

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for recombinant human glutamic acid decarboxylase (rhGAD65), (EMEA-000609-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/167/2010

of 3 September 2010

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for recombinant human glutamic acid decarboxylase (rhGAD65), (EMA-000609-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Diamyd Therapeutics AB on 22 May 2009 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 16 July 2010, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for recombinant human glutamic acid decarboxylase (rhGAD65), suspension for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for recombinant human glutamic acid decarboxylase (rhGAD65), suspension for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for recombinant human glutamic acid decarboxylase (rhGAD65), suspension for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Diamyd Therapeutics AB, Karlavägen 108, SE-115 26 Stockholm, Sweden.

Done at London, 3 September 2010

For the European Medicines Agency
Thomas Lönngren
Executive Director

(Signature on file)

EMA/PDCO/333719/2010

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-000609-PIP01-09

Scope of the application

Active substance(s):

Recombinant human glutamic acid decarboxylase (rhGAD65)

Condition(s):

Type I diabetes mellitus

Pharmaceutical form(s):

Suspension for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Diamyd Therapeutics AB

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Diamyd Therapeutics AB submitted for agreement to the European Medicines Agency on 22 May 2009 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 25 June 2009.

Supplementary information was provided by the applicant on 26 April 2010.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report :

- to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 16 July 2010

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

(Signature on file)

Annex I

The measures and timelines of the agreed Paediatric Investigation Plan and the subset(s) of the paediatric population and condition(s) covered by the waiver

1. Condition(s)

Treatment of type I diabetes mellitus

2. Waiver

2.1. Condition

Treatment of type I diabetes mellitus

The waiver applies to:

- The paediatric population from birth to less than 1 year of age;
- for suspension for injection, subcutaneous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

3. Paediatric Investigation Plan

3.1. Condition to be investigated

Treatment of type I diabetes mellitus

3.1.1. Indication targeted by the PIP

Treatment of recent-onset type I diabetes mellitus

3.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 1 to less than 18 years of age.

3.1.3. Pharmaceutical form(s)

Suspension for injection

3.1.4. Studies

Area	Number of studies	Description
Quality		Not applicable
Non-clinical		Not applicable
Clinical	5	Study #1: Randomised, double-blind, parallel-group, placebo-controlled, multicentre study, in children and adolescents between 10 and 18 years with type I diabetes mellitus, of two 20-microgram doses of rhGAD65, administered SC 4 weeks apart. Study #2: 3-arm, randomized, double-blind, placebo-controlled, multicenter, clinical trial of a prime-and-boost regimen of rhGAD65 in

		children, adolescents and adults between 10 and 20 years old, with type I diabetes mellitus. Study #3: 3-arm, randomized, double-blind, placebo-controlled, multicenter, clinical trial of a prime-and-boost regimen of rhGAD65 in children, adolescents and adults between 10 and 20 years old, with type I diabetes mellitus. Study #4: 2-arm, randomized, double-blind, placebo-controlled, multicenter, clinical trial of a prime-and-boost regimen of rhGAD65 in children, between 4 and less than 10 years old, with type I diabetes mellitus. Study #5: 2-arm, randomized, double-blind, placebo-controlled, multicenter, clinical trial of a prime-and-boost regimen of rhGAD65 in children, between 1 and less than 4 years old, with type I diabetes mellitus.
--	--	--

4. Follow-up, completion and deferral of PIP

Measures to address long term follow-up of potential safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2017
Deferral for one or more studies contained in the paediatric investigation plan:	Yes